ArticleClinical and vaccine immunology : CVI2011
Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01762930 (Study of Field Application of Oral Cholera Vaccine, Shanchol for Use in Developing Country Settings), which is not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Field Application of Oral Cholera Vaccine, Shanchol for Use in Developing Country Settings
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Long-Term Kinetics of Serological Antibodies againstInternational journal of environmental research and public health · 2022Pooled it
- Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Pooled it
- The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.Frontiers in immunology · 2026Trial
- Trial
- Trial
- Trial
- CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.Molecular medicine (Cambridge, Mass.) · 2012Trial
- Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens.Nature communications · 2025Article
- Impact of a multi-pronged cholera intervention in an endemic setting.PLoS neglected tropical diseases · 2025Article
- Article
- Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.Pharmaceutics · 2024Review
- Impact of a multi-pronged cholera intervention in an endemic setting.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Longevity of memory B cells and antibodies, as well as the polarization of effector memory helper T cells, are associated with disease severity in patients with COVID-19 in Bangladesh.Frontiers in immunology · 2022Article
- Systemic, Mucosal, and Memory Immune Responses following Cholera.Tropical medicine and infectious disease · 2021Review
- Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine.PLoS neglected tropical diseases · 2021Article
- Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine.Infection and immunity · 2021Article
- Protection afforded by previous Vibrio cholerae infection against subsequent disease and infection: A review.PLoS neglected tropical diseases · 2021Review
- Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.mSphere · 2021Article
- Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.PLoS neglected tropical diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
The mediators of protective immunity against cholera are currently unknown, but memory B-cell responses may play a central role in facilitating long-term and anamnestic responses against Vibrio cholerae, the cause of cholera. We compared memory B-cell responses in adults with natural cholera in Bangladesh (n = 70) to responses in Bangladeshi adults after one-dose (n = 30) or two-dose (n = 30) administration of an oral killed cholera vaccine, WC-rBS (Dukoral; Crucell), assessing the responses at the acute stage of disease or prevaccination and then on days 3, 30, 90, 180, 270, and 360. Individuals with natural cholera developed prominent vibriocidal and plasma anti-cholera toxin B subunit (CtxB) and lipopolysaccharide (LPS) IgG and IgA responses, but these responses returned to baseline by 1 year of follow-up. Vaccinees developed plasma anti-CtxB and anti-LPS IgG and IgA responses that were generally comparable to those in individuals recovering from natural disease, but vibriocidal responses were lower in vaccinees than in infected patients. Individuals recovering from natural disease developed memory B-cell IgG and IgA anti-CtxB and anti-LPS responses by day 30, and these responses were detectable through at least days 180 to 360. In contrast, we detected no IgA or IgG memory B-cell responses to LPS in vaccinees; anti-CtxB IgA responses were only detectable on day 30, and anti-CtxB IgG responses were detectable until days 90 to 180, compared to days 270 to 360 in patients. These findings may explain in part the relatively short-term protection afforded by oral cholera vaccination compared to natural disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.